Resources

This document is a resource list and compendium of national-level guidelines and protocols for selected countries based on the neoLENS policy review, as of February 2022.

This document highlights the health impact of a variety of medical devices and health technologies that are in use around the world, such as SoloShot syringes, HEATmarker Vaccine Vial Monitors, Nifty Feeding Cups, Uniject injection systems, and safe water devices. Innovations that have been produced at a scale of million and billions of units as well as recent product introductions addressing critical global health needs are featured.

This is a simple, Excel-based tool for assessing and comparing costs of rotavirus vaccination programs annually and for a period of 5 years with each rotavirus vaccine product available in the global market. It aims to help country-level policymakers compare products and estimate vaccination program costs for different rotavirus vaccines, exploring up to six different vaccine options at a time. The tool can be used by decision-makers, implementers, technical partners, and others in any country, whether or not the country is eligible for co-funding from Gavi, the Vaccine Alliance. Estimates of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost and cost of delivery) are provided separately, based on limited user inputs, for two perspectives: (1) the country perspective and (2) the combined country and Gavi perspective (only relevant for Gavi-eligible countries).It is important to note that cost is only one consideration when selecting a rotavirus vaccine product, and users involved in decision-making around new vaccine introduction or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results, which are provided in both tables and charts. The tool is available to download in multiple languages below. For questions or support, contact PATH's Health Economics & Outcomes Research team: HEOR@path.org.NOTE: Please refer to this web page for the most up-to-date version of the PATH Rotavirus Vaccine Cost Calculator, which is periodically updated to reflect the evolving vaccine landscape.Important update as of 21 June 2023: The calculators are currently not properly calculating co-financing amounts for countries in the “accelerated transition” phase of support from Gavi, the Vaccine Alliance. We apologize for this oversight, and we are currently working with Gavi to correct this. In the meantime, please contact your Senior Country Manager at Gavi for assistance with a cost analysis rather than using the calculators.

This is a simple, Excel-based tool for assessing and comparing costs of pneumococcal conjugate vaccine (PCV) programs annually and for a period of 10 years with each PCV product available in the global market. It aims to help country-level policymakers compare products and estimate vaccination program costs for different PCVs. The tool can be used by decision-makers, implementers, technical partners, and others in any country, whether or not the country is eligible for co-funding from Gavi, the Vaccine Alliance. Estimates of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost and cost of delivery) are provided separately, based on limited user inputs, for two perspectives: (1) the country perspective and (2) the combined country and Gavi perspective (only relevant for Gavi-eligible countries).It is important to note that cost is only one consideration when selecting a PCV product, and users involved in decision-making around new vaccine introduction or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results, which are provided in both tables and charts. The tool is available to download in multiple languages below. For questions or support, contact PATH’s Health Economics & Outcomes Research team: HEOR@path.org.NOTE: Please refer to this web page for the most up-to-date version of the PATH Pneumococcal Conjugate Vaccine Cost Calculator, which is periodically updated to reflect the evolving vaccine landscape.Important update as of 21 June 2023: The calculators are currently not properly calculating co-financing amounts for countries in the “accelerated transition” phase of support from Gavi, the Vaccine Alliance. We apologize for this oversight, and we are currently working with Gavi to correct this. In the meantime, please contact your Senior Country Manager at Gavi for assistance with a cost analysis rather than using the calculators.

The objective of this target product profile (TPP) is to describe key attributes—minimal and optimal targets—for microarray patch (MAP) delivery of COVID-19 vaccines. MAPs, also known as microneedle patches, consist of hundreds or thousands of microscopic projections that deliver dry vaccine or drug into the skin.The TPP describes key attributes for such a MAP for both LMIC and HIC markets. The document has been reviewed by a broad range of PATH staff with expertise in immunology, vaccine development, clinical trials, MAP technology, vaccine delivery, and vaccine manufacturing.